As the safety and availability of allogeneic hematopoietic stem cell transplantation (HSCT) have improved, this procedure is becoming a viable option for nonmalignant conditions such as sickle cell disease (SCD). There are very few treatment options available for SCD, and even with optimal care SCD patients still suffer from a myriad of comorbidities to multiple organ systems and have a decreased life span. In this review, we will summarize results from trials of HSCT for children or adults with SCD using a variety of graft sources as well as conditioning and graft-versus-host disease prophylaxis regimens, and discuss the unique challenges that arise in these patients.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) was originally developed as a treatment for certain relapsed or refractory hematologic malignancies. In its infancy, allogeneic HSCT was only possible for patients with a fully human leukocyte antigen (HLA)-matched sibling donor. With the development of improved regimens for graft-versus-host disease (GVHD) prophylaxis, the donor pool has expanded to include matched unrelated donors, partially HLA-mismatched related donors, and unrelated umbilical cord blood. Transplant-related mortality is approximately 10% in most recent large studies [1] [2] [3] [4] [5] . As the safety of HSCT increases, the risk of undergoing HSCT for nonfatal diseases becomes more acceptable.
Sickle cell disease (SCD) is an inherited hemoglobinopathy that causes anemia and other serious morbidities such as retinopathy, nephropathy, acute chest syndrome (ACS), stroke, venous thromboembolism, chronic pain, and acute vaso-occlusive crises. There are over 100 000 people living with SCD in the United States alone [6] , and many more in Africa and the Middle East. SCD is an attractive target for transplantation given the comorbidities and lack of approved therapies, which currently consist only of red blood cell (RBC) transfusions and hydroxyurea. Even with early identification of patients through newborn screening programs, use of available therapies, and optimal supportive care, SCD patients still have a decreased lifespan [7] . There is also a disproportionately high economic cost to patients with SCD because of disability [8] .
AlloHSCT is a potentially curative therapy for SCD because engraftment results in the replacement of recipient blood cells, including RBCs, with those of the unaffected donor. AlloHSCT is reserved only for patients with severe complications of the disease such as stroke, recurrent ACS, or frequent vasoocclusive crises because for patients with a mild phenotype, the benefits of transplantation do not currently outweigh the risks.
HUMAN LEUKOCYTE ANTIGEN-MATCHED SIBLING TRANSPLANTS
Historically, using a fully HLA-matched sibling as a donor for transplantation has been considered the gold standard in terms of safety, engraftment, and GVHD. The first use of HSCT in a SCD patient was actually performed in a child with acute myeloid leukemia. HSCT cured the leukemia but was also curative for SCD since the donor had hemoglobin AS [9] . Since that time other larger scale studies have been performed using myeloablative conditioning and HLA-matched donors and are summarized in Table 1 and below.
Walters published results of the first cohort of 22 patients who underwent transplantation for severe SCD. Two patients died, but 15 of the 20 survivors had successful engraftment and disease-free survival. End organ function was assessed prospectively, and for the patients who suffered a stroke pre-HSCT, MRI showed stable disease following transplant. In addition, patients with abnormal pulmonary function due to prior ACS had stable lung function following HSCT. This seminal study demonstrated that, although cure of SCD was possible, the high rate of graft failure was a challenge [10] .
The Center for International Blood and Marrow Transplant Research retrospectively analyzed 67 pediatric patients who were transplanted between 1989 and 2002. Patients received myeloablative conditioning, mostly with busulfan/cyclophosphamide (Bu/Cy), and GVHD prophylaxis primarily with cyclosporine and methotrexate [11] . Acute GVHD was observed in 10% of patients at 100 days, but chronic GVHD was more common with the 5-year probability being 22%. The 5-year probability of disease-free survival was 85%. Graft failure occurred in nine patients and was associated with a history of multiple RBC transfusions pretransplantation. Selfresolving veno-occlusive disease developed in four patients, three patients died, and the overall survival at 5 years was 97% [11] .
Similar outcomes have been reported by Bernaudin et al. [12] . The 87 patients in this study received myeloablative conditioning with Bu/Cy, and antithymocyte globulin (ATG) was later added to reduce the risk of graft failure. The majority received grafts from HLA-matched siblings, but four patients had donors with one HLA allele mismatch. Graft failure occurred in seven patients and was associated with transplantation prior to using rabbit ATG for conditioning. There were six transplant-related deaths,
KEY POINTS
HSCT is a curative option for SCD, and may be an appropriate therapy for patients with severe manifestations of the disease.
Graft failure remains the greatest challenge in transplantation for SCD.
The use of RIC/NMA conditioning regimens has increased the safety of transplantation, and further research is needed to tailor the conditioning regimen to optimize engraftement in this population.
The use of haploidentical donors expands the donor pool and is a well-tolerated alternative when an HLA-matched donor is unavailable. with four secondary to severe GVHD. The incidences of acute and chronic GVHD were 20% and 12.6%, respectively. Factors associated with GVHD were age greater than 15 years and HLA mismatch. Transplantation was complicated by posterior reversible encephalopathy syndrome (PRES) in seven patients. At long-term follow-up, 77 out of 81 living recipients had full donor chimerism and 79 patients were free of disease [12] . Long-term follow-up data are available for a cohort of patients who underwent HLA-matched sibling transplantation in Belgium. The first study, published in 1998, reported on 50 subjects who were analyzed in two groups. The first group (n ¼ 36) underwent HSCT because of severe comorbidities, and the second group (n ¼ 14) had less severe disease but were transplanted because they were returning to their home countries where adequate care for SCD was unavailable. Graft rejection occurred in two cases, although one was salvaged by a second transplant using the same donor. There were six cases of durable mixed hematopoietic chimerism [16] . Patients in this initial study received cyclosporine or cyclosporine plus methotrexate for GVHD prophylaxis. Eighteen patients had seizures in the peri-transplant period, and addition of seizure prophylaxis did not decrease the incidence [16] . The same group published an updated study in 2014 on 50 consecutive patients transplanted between 1988 and 2013, thus including some patients from the original cohort. Rabbit ATG was added to the conditioning after 1991, and starting in 1995 all patients were treated with hydroxyurea for at least 3 months prior to HSCT. There were no graft failures, and with a median follow-up of 8 years, overall survival of the entire cohort was 94.1% and eventfree survival was 85.6% [13 & ]. The improvement in outcomes was attributed in part to the use of hydroxyurea. In a small cohort of 24 patients, they found that recipients who had received hydroxyurea prior to HSCT and also received ATG as part of their conditioning regimen (n ¼ 13) had no graft failure [17] . They hypothesized that the decrease in CD4 þ cells from hydroxyurea [18 & ] led to decreased graft failure and hence better outcomes.
Another case series of 11 patients with SCD who underwent HLA-matched HSCT using myeloablative conditioning and cyclosporine and methotrexate for GVHD prophylaxis was recently published by a group in Spain. Of these 11 patients, one died from acute GVHD of the gut, one had secondary graft failure with reoccurrence of SCD symptoms, and one had stable mixed chimerism [14] . This cohort had a particularly good rate of engraftment, although it is not exactly clear why their outcomes were better since they used standard conditioning and GVHD prophylaxis regimens. Further analysis of this cohort should be undertaken to determine factors that contributed to high rates of engraftment.
There is a valid concern in the field regarding both the short-term and long-term effects of myeloablative conditioning, and studies are ongoing to determine how to best reduce toxicity. Nonmyeloablative (NMA) conditioning is particularly appealing for adults since their comorbidities from SCD can contribute to being a poor candidate for myeloablation. Several trials investigated the use of less toxic conditioning regimens, and are summarized in Table 2 and below. Krishnamurti et al. [19] reported on seven patients who received HLA-matched sibling bone marrow after a reduced-intensity conditioning (RIC) regimen of busulfan, fludarabine, equine ATG, and total lymphoid irradiation, with cyclosporine and mycophenolate mofetil for GVHD prophylaxis. Six of seven patients engrafted experienced resolution of all disease-related symptoms, and remain stable mixed hematopoietic chimeras following discontinuation of immunosuppression. The seventh patient did not engraft but recovered autologous hematopoiesis. Hsieh et al. [20 && ] developed a NMA protocol and, of 30 SCD patients who received HLA-matched grafts, there was no treatment-related mortality but one patient died from intracranial bleeding after relapse of SCD. An impressive 87% of patients had stable chimerism and no GVHD. Importantly, measures of morbidity such as days in hospital, narcotic use, cardiac function, and anemia were all improved after HSCT.
Horan et al. [21] tested the hypothesis that adding fludarabine to Bu/Cy and ATG would allow for dose reduction of busulfan and cyclophosphamide. Cyclophosphamide was reduced by 55% without affecting engraftment, although when they attempted to reduce the busulfan dose two patients did not achieve full donor chimerism, which triggered trial-stopping rules. All patients survived and were disease free at follow-up ranging from 9 to 23 months. There was an increase in GVHD seen in patients who received lower doses of cyclophosphamide, although this represented only four patients, so more studies will be needed to understand how the conditioning regimen influences GVHD.
Iannone et al. [22] published a report on outcomes following NMA transplantation using HLAidentical sibling grafts for six patients with SCD as well as one with thalassemia. The NMA conditioning used fludarabine, total body irradiation, and horse ATG. Only one patient had GVHD, none died, and six of seven had mixed chimerism early post-HSCT. However, as immunosuppression was tapered, all of these patients eventually lost their grafts and recovered with autologous hematopoiesis. Although the trial demonstrated that this NMA approach was safe, the outcome was disappointing and demonstrated the challenges of engraftment in this patient population.
The Sickle Cell Unrelated Donor Transplant Trial used RIC and cord blood grafts for pediatric patients with severe SCD. In this trial, only three out of eight patients engrafted and remained disease free, whereas the other five had autologous hematopoietic recovery. There was also one death from extensive chronic GVHD in this cohort [23] . Although, the incidence of graft failure in this trial was high, patients did have autologous recovery of blood counts, demonstrating relative safety of the approach and justifying further studies into less toxic conditioning regimens.
PARTIALLY HUMAN LEUKOCYTE ANTIGEN-MISMATCHED RELATED DONOR (HUMAN LEUKOCYTE ANTIGEN-HAPLOIDENTICAL) HEMATOPOIETIC STEM CELL TRANSPLANTATION
Although the outcomes of HLA-matched sibling HSCT for SCD are encouraging, it is estimated that only 15% of SCD patients have an unaffected, HLAmatched sibling [25] . In contrast, nearly every patient has an HLA-haploidentical first-degree relative, thus offering a potential solution to the problem of donor availability for patients with SCD.
Investigators at St. Jude's Research Hospital compared long-term outcomes in children receiving transplants from an HLA-matched sibling after myeloablative conditioning versus a haploidentical parent after RIC. GVHD prophylaxis in this study was cyclosporine and methotrexate. At a median follow-up of 9 years, 13 of 14 patients receiving an HLA-matched graft were alive, with the one death being attributed to chronic GVHD. At 5 years all survivors remained engrafted with greater than 85% donor chimerism. Six of eight patients receiving haploidentical transplant were alive at a median follow-up of 7 years, with the two deaths again being attributed to GVHD. However, three of eight haplorecipients experienced graft failure and recurrence of symptoms, leaving only three out of eight patients engrafted and disease free [15 && ]. All patients in both cohorts who achieved sustained engraftment achieved transfusion independence and decrease in iron load [15 && ]. The Johns Hopkins experience of HSCT for SCD was published in 2012 and included three patients who had an HLA-matched donor and 14 with haploidentical-related donors. The NMA regimen included fludarabine, cyclophosphamide, TBI, and ATG. Patients received high dose posttransplantation cyclophosphamide, mycophenylate mofetil, and either tacrolimus or sirolimus for GVHD prophylaxis. The incidence of graft failure was 43% in haploidentical pairs. However, there was no mortality in this study and only one patient had GVHD of the skin only that did not require treatment. All patients who engrafted became transfusion independent, and of the 17 patients who started the trial, a striking 41% are no longer taking narcotics [24] . The results are encouraging that in the future, transplant can become a more widely utilized and safe option for patients with this chronic disease.
UNIQUE CHALLENGES IN TRANSPLANTATION FOR SICKLE CELL DISEASE
The experience with transplantation in this population has identified several unique challenges as outlined in Table 3 . HSCT is known to affect fertility in all patient populations. A study assessed the ovarian reserve of young female SCD patients who had undergone HSCT. Of the nine HSCT patients assessed, all of them had undetectable antimullerian hormone and 89% has follicle-stimulating hormone levels in the menopausal range [26] . Similar results were found in the study by Dallas et al. [15 && ], in which only five of nine males and two of four females had normal gonadal function following transplantation. Patients in this study had received myeloablative conditioning, so further study must be done to assess the effect of NMA conditioning on fertility. In a separate prospective trial, over half of female recipients of HSCT had diminished ovarian reserve, and only three of 13 males had normal testosterone levels following HSCT, consistent with a diagnosis of hypogonadotropic hypogonadism [27] . Ovarian hyperstimulation and oocyte preservation has been done successfully in SCD patients prior to undergoing HSCT [28] , and sperm cryopreservation is also possible. It is particularly important for physicians to be proactive about discussing fertility preservation including the use of gamete or embryo cryopreservation since many SCD patients are being transplanted at young ages before they are ready to consider child-bearing.
The aforementioned studies demonstrate that graft failure is clearly a major challenge in transplantation for SCD. This is in stark contrast to alloHSCT for hematologic malignancies, where graft failure is below 5% in recent studies [1, 3, 29, 30] . Unlike hematologic malignancy patients, SCD patients are not exposed to cytotoxic chemotherapy prior to transplant conditioning and so have intact immune systems that can mediate graft failure. Allosensitization through multiple RBC transfusions also increases the risk of graft failure for patients with SCD. Intensification of the conditioning regimen reduces the risk of graft failure but increases toxicity to vital organs and increases the risk of severe GVHD, an unacceptable complication of alloHSCT for nonmalignant disorders. In our opinion, the biggest challenge in alloHSCT for SCD is to develop a conditioning regimen that minimizes toxicity without compromising engraftment.
AlloHSCT in the SCD population has a higher incidence of neurological toxicity than patients who are transplanted for other diseases. While the etiology of this is not known, many patients with SCD have preexisting strokes or silent cerebral infarcts and so may have a low threshold for further damage. In the Belgian study, six out of 50 patients developed PRES. The majority of patients in this trial received cyclosporine and methotrexate for GVHD prophylaxis, with the remainder receiving cyclosporine alone (UCB recipients) or cyclosporine and mycophenolate mofetil. Changing GVHD prophylaxis to sirolimus significantly reduced the incidence of PRES in our cohort [24] . Patients who undergo HSCT for SCD also have a higher incidence of seizures in the peri-transplant period than do other populations. All patients receive anticonvulsants for prophylaxis but this has met with varying degrees of success. Further research is needed to understand the mechanisms behind the neurological complications unique to this population.
CONCLUSION
Allogeneic HSCT is a curative option for patients with HSCT. Currently, it is only used for patients with severe manifestations of the disease, but as we optimize conditioning regimens and GVHD prophylaxis and safety continually increases, this 
High incidence of PRES
Use alternative methods such as sirolimus for GVHD prophylaxis. Use of anticonvulsants is standard but has not proven to be effective.
Incidence of infertility
Fertility preservation including offering gamete retrieval and cryopreservation should be discussed with all patients and their families prior to HSCT.
Chronic pain posttransplant
Consider a multidisciplinary approach with psychiatry, neurology, and behavioral therapy.
GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; PRES, posterior reversible encephalopathy syndrome; SCD, sickle cell disease.
may become a more widely utilized option. Small numbers of patients have undergone transplants from haploidentical donors, which has been shown to be safe and results are encouraging that in the future this procedure may be available for more patients as the donor pool expands. Graft failure remains the most significant challenge, and more research in preclinical models as well as clinical trials are needed.
